DRG Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key neuropathic back pain patient populations covering 171 countries and more…
DRG Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each…
DRG Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of NBP for each country, as…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
DRG Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…
Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…